Video

Expert forum on prostate cancer survivorship: Future research

Author(s):

Urology Times staff

In this video, Marta Skrodzka, MD, PhD, FEBU, FECSM, FEAA, Jai Seth, MD, BSc, MSc, FRCS, and Netty Kinsella, RN, MSc, PhD, discuss upcoming research in the areas of individualized care, sexual dysfunction, and stratified follow-up. This discussion is part of a larger forum on prostate cancer survivorship. Skrodzka is a consultant urologist and Seth is a urology consultant at St George’s University Hospital, and Kinsella is a uro-oncology nurse consultant at the Royal Marsden NHS Foundation Trust in London, United Kingdom.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell
Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
© 2025 MJH Life Sciences

All rights reserved.